Enterprise Value
4.523B
Cash
170.5M
Avg Qtr Burn
-97.36M
Short % of Float
30.20%
Insider Ownership
77.59%
Institutional Own.
9.97%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Anktiva (N-803) + BCG Details Bladder cancer, Cancer | Approved Quarterly sales | |
PD-L1 t-haNK Details Pancreatic cancer, Cancer | Phase 2/3 Update | |
Anktiva (N-803) + checkpoint inhibitors Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 2 Update | |
hAd5-COVID-19 Details Vaccine, COVID-19 | Failed Discontinued | |
N-803 (Anktiva), haNK and Avelumab Details Metastatic merkel cell carcinoma, Insomnia, Mood disorders, Liver transplant, Cancer | Failed Discontinued |